Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
Phosphorus levels are higher when blood specimens are collected after weekends.
Paricalcitol-based protocol includes limited use of calcium-based phosphate binders.
The control of phosphorus is underappreciated, for example.
Average 6-month serum phosphorus level was significantly lower in CKD patients who received niacin than those who did not (3.4 vs. 4.2 mg/dL).
Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.
Small case series also confirmed that the diagnosis of calciphylaxis is rarely made in the nodular, non-ulcerative phase.
Study of peritoneal dialysis patients showed that they do not adjust binders to match the phosphate content of meals and snacks.
A low protein diet of vegetable proteins along with reduced intake of specific micronutrients should be recommended to stage 3-4 CKD patients, researchers say.
Expert suggests factors beyond poor adherence to a low phosphorus diet and binder therapy may contribute to hyperphosphatemia.
Study compared sucroferric oxyhydroxide and sevelamer carbonate.
The risk of dying following a hip fracture was 6.5 times higher for patients with severe CKD than for those with normal kidney function or mild CKD.
Phosphate and vitamin D deficiency were linked with RLS severity.
Researchers observe a 2.2-fold increased risk in patients with serum phosphate levels of 6.0 mg/dL or higher.
Meta-analysis finds that each 1 mg/dL increase in serum phosphate increases the risk of death by 23%.
Researchers observe a significant mean decrease in binder pills from 8.4 to 3.8 pills per day.
Cumulative 2-year survival rate was 65.4%, 78.9%, 85.1%, and 80.6% among patients in the 1st, 2nd, 3rd, and 4th quartiles.
About 3 additional deaths per 100 persons occur when the drug is discontinued due to non-medical versus medical reasons during the first year.
Significant decreases in serum phosphate and erythropoietin dose in hemodialysis patients observed after 6 months of treatment.
Very low protein intake was not superior to traditional low protein diets, however.
Recipients of in-hospital nighttime dialysis experienced a 14.2 gram reduction in left ventricle thickening.
Even healthy adults show evidence of abnormal bone metabolism.
Researchers find link in the non-dialysis population.
Large South Korean study demonstrates the association in individuals with normal kidney function.
Large European study identifies ranges of phosphorus, calcium, and parathyroid hormone levels with the lowest death risk.
African-American patients, however, had significantly higher intact parathyroid hormone levels, possibly due to lower 25-hydroxyvitamin D levels.
Every 1 mg/dL increase in serum phosphorus level was linked with 36% greater odds of kidney failure among non-dialysis CKD patients.
- Blacks With Diabetes and CKD Have Higher CVD Risk
- Worse Re-transplant Outcomes for HIV Positive Patients
- Race, Procedure Type Influence Morbidity in Pediatric Surgery Patients
- Parathyroidectomy Rates Stable Despite Changes in Medical Therapy
- Early Recurrence After Laparoscopic Radical Cystectomy Explored
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)